Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.381
Neutral
RSI(14)
41.513
Neutral
STOCH(KDJ)(9,3,3)
42.269
Sell
ATR(14)
1.026
Low Volatility
CCI(14)
-34.454
Neutral
Williams %R
62.100
Sell
TRIX(12,20)
-0.475
Sell
StochRSI(14)
9.250
Sell
Caris Life Sciences Inc
CAI16.730USD
-1.830-9.86%
Market hours （ET）Quotes delayed by 15 min
4.65BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Caris Life Sciences Inc
Currency: USD Updated: 2026-03-26Key Insights
Caris Life Sciences Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered undervalued, ranking 60 out of 209 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 32.80.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Caris Life Sciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Caris Life Sciences Inc Highlights
StrengthsRisks
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 165.26% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 812.03M.
Undervalued
The company’s latest PE is -5.70, at a low 3-year percentile range.
Held by Invesco
Star Investor Invesco holds 36.76K shares of this stock.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
32.800
Target Price
+70.48%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-26The current financial score of Caris Life Sciences Inc is 8.72, ranking 18 out of 209 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.51
Operational Efficiency
8.38
Growth Potential
10.00
Shareholder Returns
7.73
Caris Life Sciences Inc's Company Valuation
Currency: USD Updated: 2026-03-26The current valuation score of Caris Life Sciences Inc is 6.85, ranking 143 out of 209 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -5.70, which is -38.68% below the recent high of -3.49 and -8.35% above the recent low of -6.17.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 60/209
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-26The current earnings forecast score of Caris Life Sciences Inc is 8.80, ranking 14 out of 209 in the Healthcare Equipment & Supplies industry. The average price target is 39.00, with a high of 45.00 and a low of 28.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
32.800
Target Price
+70.48%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
115
Total
6
Median
9
Average
Company name
Ratings
Analysts
Caris Life Sciences Inc
CAI
10
Medtronic PLC
MDT
34
Stryker Corp
SYK
32
Zimmer Biomet Holdings Inc
ZBH
31
Abbott Laboratories
ABT
31
Dexcom Inc
DXCM
31
1
2
3
...
23
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-26The current price momentum score of Caris Life Sciences Inc is 6.58, ranking 130 out of 209 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 20.70 and the support level at 16.73, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
18.760
Sell
MA10
18.682
Sell
MA20
18.926
Sell
MA50
21.246
Sell
MA100
24.009
Sell
MA200
27.526
Sell
Institutional Confidence
Currency: USD Updated: 2026-03-26Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Halbert (David D)
J.H. Whitney Capital Partners, LLC
Sixth Street Partners, LLC
Fidelity Management & Research Company LLC
Castleman Peter M
T. Rowe Price Investment Management, Inc.
Braidwell LP
PointState Capital LP
1
2
Risk Assessment
Currency: USD Updated: 2026-03-26The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Caris Life Sciences Inc is 5.34, ranking 83 out of 209 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
--
VaR
--
240-Day Maximum Drawdown
--
240-Day Volatility
--
Return
Best Daily Return
60 days
--
120 days
--
5 years
--
Worst Daily Return
60 days
--
120 days
--
5 years
--
Sharpe Ratio
60 days
--
120 days
--
5 years
--
Risk Assessment
Maximum Drawdown
240 days
--
3 years
--
5 years
--
Return-to-Drawdown Ratio
240 days
--
3 years
--
5 years
--
Skewness
240 days
--
3 years
--
5 years
--
Volatility
Realised Volatility
240 days
--
5 years
--
Standardised True Range
240 days
--
5 years
--
Downside Risk-Adjusted Return
120 days
--
240 days
--
Maximum Daily Upside Volatility
60 days
--
Maximum Daily Downside Volatility
60 days
--
Liquidity
Average Turnover Rate
60 days
--
120 days
--
5 years
--
Turnover Deviation
20 days
--
60 days
--
120 days
--
Peer Comparison
Healthcare Equipment & Supplies
Caris Life Sciences Inc
CAI
7.12 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
ANIK
8.64 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
TMO
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bioventus Inc
BVS
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
West Pharmaceutical Services Inc
WST
8.26 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
LNTH
8.12 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
